Change in circulating C-reactive protein is not associated with atorvastatin treatment in Alzheimer's disease

REFERENCES

• de la Torre JC. Critically attained threshold of cerebral hypoperfu-sion: The CATCH hypothesis of Alzheimer's pathology. Neurobiol Aging 2000; 21: 331–342
   PubMed Web of Science ®Google Scholar
• Sparks DL, Saunders AM, Scheff SW, et al. Increased density of cortical senile plaques (SP) in non-demented individuals with the apol ipoprotein-E4 genotype. Neurobiol Aging 1994; 15: S144—S145
   Google Scholar
• Sparks DL, Hunsaker JC 3rd, Scheff SW, et al. Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease. Neurobiol Aging 1990; 11: 601–607
   PubMed Web of Science ®Google Scholar
• Khachaturian ZS. Diagnosis of Alzheimer's disease. Arch Neurol 1985; 42: 1097–1105
   PubMed Web of Science ®Google Scholar
• Sparks DL, Scheff SW, Liu H, et al. Increased incidence of neurofibrillary tangles (NET) in non-demented individuals with hypertension. J Neurol Sci 1995; 131: 162–169
   PubMed Web of Science ®Google Scholar
• Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141–1145
   PubMed Web of Science ®Google Scholar
• Kivipelto M, Helkala EL, Hallikainen M, et al. Elevated systolic blood pressure and high cholesterol levels at midlife are risk factors for late-life dementia. Neurobiol Aging 2000; 21 (Suppl. 1): S174
   Google Scholar
• Hartmann T. Cholesterol, A beta and Alzheimer's disease. Trends Neurosci 2001; 24 (Suppl. 11): S45—S48
   Google Scholar
• Sparks DL. Vascular related and mediated alterations in Alzheimer's disease. Cerebral Cortex 1999; 14: 733–772
   Google Scholar
• Reitz C, Tang MX, Luchsinger JA. Relation of plasma lipids to Alzheimer's disease and vascular dementia. Arch Neurol 2004; 61: 705–714
   PubMed Web of Science ®Google Scholar
• Bodovitz S, Klein WL. Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J Biol Chem 1996; 271: 4436–4440
   PubMed Web of Science ®Google Scholar
• Sparks DL, Connor DJ, Wasser DR, et al. The Alzheimer's Disease Atorvasta tin Treatment Trial: Scientific Basis and Position on the Use of HMG-CoA Reductase Inhibitors (Sta tins) that do or do not Cross the Blood—Brain Barrier. Advances in Drug discovery and Drug Development for Cognitive Aging and Alzheimer's Disease, Springer Publishing Co., 2000: pp. 244-252
   Google Scholar
• DeKosky ST. Statin therapy in the treatment of Alzheimer's disease: What is the rationale? Am J Med 2005; 118: S48—S53
   Google Scholar
• Rockwood K, Kirkland S, Hogan DB, et al. Use of Lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 2002; 59: 223–227
   PubMed Web of Science ®Google Scholar
• Etminan M, Gill S, Samii A. The role of lipid-lowering drugs in cognitive function: A meta-analysis of observational studies. Pharmacotherapy 2003; 23: 726–730
   PubMed Web of Science ®Google Scholar
• Zamrini E, McGwin G, Roseman JM. Association between statin use and Alzheimer's disease. Neuroepidemiology 2004; 23: 94-98
   Google Scholar
• Masse I, Bordet R, Deplanque D, et al. Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2005; 76: 1624-1629
   Google Scholar
• Bernick C, Katz R, Smith NL, et al. Statins and cognitive function in the elderly. The cardiovascular health study. Neurology 2005; 65: 1388–1394
   PubMed Web of Science ®Google Scholar
• Verma S, Szmitko PE, Ridker PM. C-reactive protein comes of age. Nat Clin Pract Cardiovasc Med 2005; 2: 29–36
   PubMedGoogle Scholar
• Albert CM, Ma J, Rifai N, et al. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 2002; 105: 2595–2599.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836–843
   PubMed Web of Science ®Google Scholar
• Yasojima K, Schwab C, McGeer EG, et al. Human neurons generate C-reactive protein and amyloid P: Upregulation in Alzheimer's disease. Brain Res 2000; 887: 80–89
   PubMed Web of Science ®Google Scholar
• Bassuk SS, Rifai N, Ridker PM. High-sensitivity C-reactive protein: Clinical importance. Curr Probl Cardiol 2004; 29: 439–493
   PubMed Web of Science ®Google Scholar
• Ford ES, Giles WH, Myers GL, et al. C-reactive protein concentration distribution among US children and young adults: Findings from the National Health and Nutrition Examination Survey, 1999-2000. Clin Chem 2003; 49: 1353–1357
   PubMed Web of Science ®Google Scholar
• Ray KK, Cannon CP, Cairns R, et al. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial.] Am Coll Cardiol 2005; 46: 1417–1424
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001; 103: 1191–1193
   PubMed Web of Science ®Google Scholar
• Mora S, Ridker PM. Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER)-can C-reactive protein be used to target statin therapy in primary prevention? Am] Cardiol 2006; 97 (2A): A33—A41
   Google Scholar
• Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 20-28
   Google Scholar
• Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004; 109 (Suppl. 1): 112-1110
   Google Scholar
• Duong T, Acton PJ, Johnson RA. The in vitro neuronal toxicity of pentraxins associated with Alzheimer's disease brain lesions. Brain Res 1998; 813: 303–312
   PubMed Web of Science ®Google Scholar
• Iwamoto N, Nishiyama E, Ohwada J, et al. Demonstration of CRP immunoreactivity in brains of Alzheimer's disease: Immunohistochemical study using formic acid pretreatment of tissue sections. Neurosci Lett 1994; 177: 23–26
   PubMed Web of Science ®Google Scholar
• Wood JA, Wood PL, Ryan R, et al. Cytokine indices in Alzheimer's temporal cortex: no changes in mature IL-1 beta or IL-1 RA but increases in the associated acute phase proteins IL-6, alpha 2-macroglobulin and C-reactive protein. Brain Res 1993; 629: 245–252
   PubMed Web of Science ®Google Scholar
• Licastro F, Chiappelli M, Ruscica M, et al. Altered cytokine and acute phase response protein levels in the blood of children with Downs syndrome: Relationship with dementia of Alzheimer's type. Int] Immunopathol Pharmacol 2005; 18: 165–172
   Google Scholar
• Dik MG, Jonker C, Hack CE, et al. Serum inflammatory proteins and cognitive decline in older persons. Neurology 2005; 64: 1371–1377
   PubMed Web of Science ®Google Scholar
• Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the mental state of patients for the cl in ic ian. J Psychiatric Res 1975; 12: 189–198
   PubMed Web of Science ®Google Scholar
• Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's Disease. Am J Psychiatry 1984; 141:1356–1364
   PubMed Web of Science ®Google Scholar
• Kaufer DI, Cummings JL, Cristine EL. Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: The Neuropsychiatric Inventory Caregiver distress Scale. J Amer Geriatr Soc 1998; 46: 210–215
   PubMed Web of Science ®Google Scholar
• Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11: S22—S32
   Google Scholar
• Galasko D, Corey-Bloom J, Thal U. Monitoring progression in Alzheimer's disease. J Am Geriatr Soc 1991; 39: 932–941
   PubMed Web of Science ®Google Scholar
• Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11 (Suppl. 2): S33—S39
   Google Scholar
• Yesavage JA. Geriatric Depression Scale. Psychopharmacol Bull 1988; 24: 709–711
   PubMed Web of Science ®Google Scholar
• Sparks DL, Sabbagh MN, Connor DJ, et al. Atorvastatin for the treatment of mild to moderate Alzheimer's disease: Preliminary results. Arch Neurol 2005; 62: 753–757
   PubMed Web of Science ®Google Scholar
• Sparks DL, Petanceska S, Sabbagh M, et al. Cholesterol, copper and Abeta in controls, MCI, AD and the AD cholesterol-lowering treatment trial (ADCLT). Curr Alzheimer Res 2005; 2: 527–39
   PubMedGoogle Scholar